Tacrolimus Plus Low-Dose Mycophenolate Mofetil in Renal Transplant Recipients: Better 2-Year Graft and Patient Survival Than With a Higher Mycophenolate Mofetil Dose

• Published in: Transplantation proceedings Vol. 37; no. 7; pp. 3009 - 3011
• Main Authors: Kocak, H., Yakupoglu, U., Karatas, G. Uslu, Yavuz, A., Gurkan, A., Erdogan, O., Ersoy, F.F., Yakupoglu, G., Demirbas, A., Tuncer, M.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01-09-2005; Elsevier Science
• Subjects: Adult; Biological and medical sciences; Creatinine - blood; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Graft Rejection - epidemiology; Graft Survival - drug effects; Graft Survival - immunology; Humans; Kidney Transplantation - immunology; Kidney Transplantation - mortality; Male; Medical sciences; Middle Aged; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Survival Analysis; Tacrolimus - therapeutic use; Tissue, organ and graft immunology; Mofetil; Mycophenolic acid; Prognosis; Calcineurin inhibitor; Transplantation; Homotransplantation; Posology; Kidney; Surgery; Antiviral; Graft; Human; Drug combination; Low dose; Lactone; Patient; Macrolide; Survival; Immunomodulator; Medicine; Antibiotic; Treatment; Urinary system; Tacrolimus; Immunosuppressive agent; Mycophenolate mofetil; Antibacterial agent
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2005.07.033

Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demographic features and clinical data for 173 renal transplant recipients who received tacrolimus (TAC) plus 1 g/d MMF (group I, n = 112) versus TAC plus 2 g/d MMF (group II, n = 61 patients) over a 2-year period. Each patient received similar TAC doses.
We compared demographic data and clinical data for each case: acute rejection (AR) episodes, chronic rejection (CR) episodes, death, graft loss, development of posttransplantation diabetes mellitus (PTDM), and posttransplantation hypertension rates.
Demographic features were similar. There were also no significant differences between groups I and II with respect to number of AR episodes (17/112 vs 12/61, respectively), number of CR episodes (4/112 vs 1/61, respectively), PTDM, and hypertension rate (
P > .05). Kaplan-Meier survival analysis revealed 2-year graft survival rates of 94% in group I versus 83% in group II. The corresponding 2-year patient survival rates were 100% in group I versus 91% in group II. The graft survival and patient survival rates in group I were significantly higher than those in group II (log-rank 0.005 and 0.001, respectively).
The 2-year graft and patient survival rates for the renal transplant recipients in this study suggest that the combination of a full TAC dose with 1 g/d MMF is a better choice than 2 g/d MMF.